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Structure-Based Discovery of a Novel,
Noncovalent Inhibitor of AmpC -Lactamase
tors are required to avoid such preevolved resistance
mechanisms. Inhibitors that do not chemically and
structurally resemble -lactams would not be hy-
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and Biological Chemistry drolyzed by -lactamases and would not be recognized
by sensor proteins that bind -lactams and upregulateNorthwestern University
303 East Chicago Avenue the expression of -lactamases [3]. Additionally, a novel
inhibitor may not be affected by porin channel mutants,Chicago, Illinois 60611
which prevent -lactams from accessing their cellular
targets. An inhibitor that does not resemble a -lactam
minimizes the ability of bacteria to recruit existing resis-Summary
tance mechanisms, and novel mechanisms would need
to be developed.-lactamases are the most widespread resistance
Several classes of non--lactam inhibitors of -lacta-mechanisms to -lactam antibiotics, and there is a
mases have been identified. Transition-state analog in-pressing need for novel, non--lactam drugs. A data-
hibitors (Figure 1C), such as boronic acids and phospho-base of over 200,000 compounds was docked to the
nates, inhibit both class A and class C -lactamasesactive site of AmpC -lactamase to identify potential
[4, 5]. Much effort has been devoted to improving theinhibitors. Fifty-six compounds were tested, and three
binding affinities of these molecules [3, 6–9]. One con-had Ki values of 650 M or better. The best of these,
cern with both types of molecules is that they form3-[(4-chloroanilino)sulfonyl]thiophene-2-carboxylic
covalent adducts with activated serine nucleophiles, po-acid, was a competitive noncovalent inhibitor (Ki  26
tentially reducing their selectivity versus other serineM), which also reversed resistance to -lactams in
active enzymes, such as serine proteases. A noncova-bacteria expressing AmpC. The structure of AmpC in
lent inhibitor may be better suited as a candidate leadcomplex with this compound was determined by X-ray
in drug development for this reason.crystallography to 1.94 A˚ and reveals that the inhibitor
In an effort to identify a novel, noncovalent inhibitorinteracts with key active-site residues in sites targeted
of AmpC -lactamase, we used a structure-based ap-in the docking calculation. Indeed, the experimentally
proach, beginning with a consensus map of “hot spots”determined conformation of the inhibitor closely re-
on the enzyme. The consensus map was recently con-sembles the prediction. The structure of the enzyme-
structed from crystal structures of AmpC in complexesinhibitor complex presents an opportunity to improve
with 13 different ligands [10]. This map was used as abinding affinity in a novel series of inhibitors discov-
template in a molecular docking calculation to screenered by structure-based methods.
a database of over 200,000 small molecules for comple-
mentarity to the binding site. Based on the results of
Introduction this screen, we ordered and tested 56 compounds for
inhibition of AmpC; three of these had apparent Ki values
-lactams, such as penicillins and cephalosporins, are of 650M or better. The best of the three, 3-[(4-chloroan-
the most widely prescribed class of antibiotics (Figure ilino)sulfonyl]thiophene-2-carboxylic acid (compound 1;
1A). In response to their extensive use and misuse, resis- Figure 1D), was a competitive inhibitor of AmpC with a
tance to these drugs has become widespread. Their Ki value of 26 M (Table 1) and was able to reversecontinued utility is threatened by the expression of resistance in bacterial cell culture. The structure of
-lactamase enzymes, the most pervasive resistance AmpC in complex with compound 1 was determined to
mechanism to this class of antibiotics [1, 2]. These en- 1.94 A˚ resolution by X-ray crystallography and was
zymes hydrolyze the lactam ring and render the antibi- found to closely resemble the docking prediction.
otic inactive against its original cellular targets, the cell
wall transpeptidases. Results
In an effort to combat -lactamase enzymes, -lacta-
mase inhibitors, such as clavulanic acid, and -lacta- Docking
mase-resistant compounds, such as the third-genera- The Northwestern University version [11, 12] of DOCK
tion cephalosporins, have been introduced (Figure 1B). [13, 14] was used to screen the Available Chemicals
Bacteria responded rapidly to these compounds be- Directory, a database of 229,810 commercially available
cause the compounds are themselves -lactams. Exist- small molecules, against the crystallographic structure
ing resistance mechanisms, including -lactamases, of AmpC-lactamase. The docking experiment incorpo-
porin channel mutations, and sensor proteins, recognize rated information about hot spots identified on AmpC
and respond to the lactam ring functionality common to using a consensus overlay [10]. Two docking calcula-
both substrates and inhibitors alike. These mechanisms tions, differing in the partial atomic charges assigned
are easily disseminated among bacteria, allowing resis- to several active site residues, were performed (see Ex-
tance to these inhibitors to spread rapidly. Novel inhibi-
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and electrostatic contributions to binding. Increasing
the partial atomic charges of receptor atoms in this way
is an ad hoc solution to this problem and may not be
generally useful. In this case, this solution did result in
the emergence of putative ligands with improved polar
complementarity to AmpC from the docking calculation.
The 500 top-scoring molecules from each docking run
were examined graphically for complementarity to the
enzyme, for polar interactions with active site residues,
and for agreement with binding sites identified in the
consensus map. The lists were filtered for compounds
that had been incorrectly represented in the database.
From the two lists, we ordered and tested 56 compounds
for inhibition of AmpC. Three molecules inhibited AmpC
with Ki values of 650M or better (compounds 1–3; Table
1). Compound 1 ranked 70th out of 229,810, compound 2
ranked 339th, and compound 3 ranked 370th in the hit
list from the calculation using the larger dipoles; these
compounds were not present in the other top 500 list.
The DOCK-predicted conformations of these com-
pounds and their interactions with AmpC are shown
in Figure 2. Compound 1 is a competitive, reversible
inhibitor with a Ki value of 26 M for AmpC, as deter-
mined by Lineweaver-Burk analysis (Figure 3). This com-
pound was also tested for activity against the serine
proteases -chymotrypsin, -trypsin, and elastase (Ta-
ble 1). Compound 1 showed no inhibition of trypsin and
elastase at concentrations up to 4 mM and was approxi-
mately 50-fold more selective for AmpC over chymo-
trypsin.
Several intriguing interactions are observed between
AmpC and compound 1 in the DOCK-predicted confor-
mation (Figure 2A; Table 2). The carboxylate group is
placed near the catalytic Ser64. One of the oxygens of
the carboxylate interacts with O of Ser64 and the main
chain nitrogen of Ala318 and makes a close polar con-
tact with the main chain oxygen of Ala318; the other
oxygen interacts with the main chain nitrogen of Ala318
and Wat403, a conserved water molecule that was in-
cluded in the docking experiment as part of the receptor.
The thiophene ring of the inhibitor is placed in the hy-
drophobic binding site formed by Leu119 and Leu293.
One of the sulfonamide oxygens interacts with O of
Ser64, and the other oxygen interacts with N2 of
Asn152. The nitrogen of the sulfonamide interacts with
the main chain oxygen of Ala318. Finally, the chlorophe-
nyl ring appears to stack with Tyr221. Several of these
Figure 1. Comparison of the Chemical Structures of Several
interactions agree with the consensus hot spot map;
-Lactamase Ligands
the Leu119/Leu293 hydrophobic patch is comple-(A) Ampicillin, a -lactamase substrate.
mented with the thiophene ring, the amide recognition(B) Ceftazidime, a -lactamase-resistant molecule. The R1 side
region defined by Asn152 and Ala318 hydrogen bondschain ubiquitous among -lactams is labeled.
(C) A boronic acid transition-state analog inhibitor that contains the to the sulfonamide, and one of the carboxylate oxygens
R1 side chain from ceftazidime [9]. is placed in the “oxyanion” [15] or “electrophilic” [3]
(D) Compound 1, 3-[(4-chloroanilino) sulfonyl]thiophene-2-carbox- hole, which can bind carbonyl and hydroxyl groups.
ylic acid, a novel, competitive inhibitor of -lactamase.
perimental Procedures). The magnitudes of local partial Crystallography
Subsequently, the structure of AmpC in complex withatomic charges were increased, without changing the
overall charges of the residues, in an effort to better compound 1 was determined by X-ray crystallography
to 1.94 A˚ resolution (Figure 4A; Table 3). The locationcapture the polarization thought to occur when ligands
hydrogen bond to these residues. In our experience, of the inhibitor in each of the two active sites was unam-
biguously identified in the initial Fo  Fc difference mapsDOCK and the Northwestern University version of this
program used here underrepresent hydrogen bonding when contoured at 3 . In addition, Fo  Fc difference
Docking for Novel Inhibitors of -Lactamase
1015
Table 1. Kinetic Characterization of DOCK-Predicted Inhibitors of AmpC
Kia (M) IC50 (M) IC50 (M) IC50 (M)
Code Structure AmpC Chymotrypsin Trypsin Elastase
261 	1,200 	4,000 	4,000
3182 NDb ND ND
6463 ND ND ND
a Accurate to within 20%.
b Not determined.
electron density indicated the presence of a third inhibi- Tyr221; the distance between the centroids of these
two rings is between 5.5 and 5.8 A˚, and the angle oftor molecule located at the interface between the two
molecules. Since this interface occurs only in AmpC interaction ranges from 91
 to 94
.
The DOCK-predicted conformation of compound 1crystals and not in solution, where AmpC is thought to
be monomeric, we consider this site to be an artifact of closely resembles the experimentally determined struc-
ture (Figure 4C); the rmsd for all inhibitor atoms is 1.87 A˚crystallography. The electron density from a simulated-
annealing omit map of the inhibitors in the refined model for molecule 2 and 1.75 A˚ for molecule 1 of the crystal
structure. Much of the rms difference between the pre-agreed well with the modeled conformation in each site
(data not shown). The quality of the final model of the dicted and experimental structures arises from a rota-
tion of the distal chlorophenyl ring about an internalcomplex was analyzed with the program Procheck [16];
92.5% of the nonproline, nonglycine residues are in the bond and a rocking motion of the entire molecule about
an axis defined by the hydrogen bonding groups thatmost-favored region of the Ramachandran plot (7.5%
in the additionally allowed region). Comparison with the line the “bottom” side, i.e., the side facing the active
site residues. Indeed, when only the inhibitor atoms thatstructure on which the docking calculation was per-
formed showed that active site residues do not change are involved in hydrogen bonds (N1, O16, O17, O23, and
O24) are included in the analysis, the rmsd becomesmuch upon complex formation (rmsd for all atoms of
Ser64, Lys67, Tyr150, Asn152, Tyr221, Lys315, and 0.94 A˚ for molecule 2 and 0.95 A˚ for molecule 1.
In the crystal structure, the inhibitor is shifted andAla318 was 0.22 A˚ for molecule 2 and 0.24 A˚ for mole-
cule 1). slightly rotated from the predicted conformation. De-
spite this shift, most of the interactions between AmpCIn the experimentally determined structure, com-
pound 1 interacts with several active site residues (Fig- and compound 1 in the predicted conformation are also
observed in the experimental structure. Of the nine hy-ure 4B; Table 2). The carboxylate group is bound near
Ser64, with one of its oxygens interacting with the main drogen bonding interactions observed in both mono-
mers in the crystallographic complex, seven are alsochain nitrogen and O atoms of Ser64 and the main
chain nitrogen of Ala318. The other oxygen of the car- observed in the docked prediction (Table 2). Corre-
spondingly, of the eight hydrogen bonding interactionsboxylate hydrogen bonds to Wat403 and, in molecule
2, to Wat481. The thiophene ring is within van der Waals predicted in the docked structure, only one is not ob-
served crystallographically. For instance, the key inter-distance to residues Leu119 and Leu293 (distances
range from 4.2 to 4.6 A˚), which form a hydrophobic actions between the sulfonamide oxygen O17 and
Asn152N2 and between the sulfonamide nitrogen N1patch on AmpC. One of the sulfonamide oxygen atoms
hydrogen bonds to O of Ser64 and N of Lys67; the and Ala318O are observed in both the experimental and
predicted structures. On the other hand, interactionsother interacts with N2 of Asn152. The nitrogen atom
of the sulfonamide group interacts with the main chain between the sulfonamide oxygen O16 and Lys67N and
between the carboxylate oxygen and Ser64N are onlyoxygen of Ala318. The chlorophenyl ring appears to be
involved with quadrupole-quadrupole interactions with observed in the crystal structure. The largest difference
Structure
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Figure 2. Stereo View of the Interactions Observed between AmpC and Compounds 1–3 in the DOCK-Predicted Orientations
(A) Compound 1.
(B) Compound 2.
(C) Compound 3.
Carbon atoms of the ligands, green; nitrogens, blue; oxygens, red; sulfurs, yellow; chlorines, magenta. Atomic interactions within hydrogen
bonding distance are shown as dashed yellow lines. The cyan sphere labeled 403 in (A) represents Wat403; for clarity, Wat403 is not shown
in (B) and (C). This figure and Figures 4B and 4C were generated with MidasPlus [31].
between the two structures is the orientation of the chlo- Microbiology
We investigated the ability of compound 1 to potentiaterophenyl ring; in the crystal structure, this ring has ro-
tated approximately 60
, as measured by the dihedral the activity of a -lactam against a strain of resistant
bacteria that overexpresses AmpC. In bacterial cell cul-angle around S13, N1, C2, and C3. This ring now inter-
acts in a more edge to face manner with Tyr221, presum- ture, the potency of ampicillin when given in combina-
tion with compound 1 is increased 4-fold, reducing itsably making quadrupole-quadrupole interactions with
Tyr221, instead of the parallel face to face interaction minimum inhibitory concentration (MIC) to 128 g/ml
(Table 4). The MIC of ampicillin in the absence of com-predicted by docking.
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was abolished when this group was replaced with a
methyl ester (compound 5) or a nitro group (compound
9). Switching the atom order of the sulfonamide group
(compound 4), which hydrogen-bonds with Asn152 and
Ala318, reduced affinity 3-fold. Disruption of the proton-
donating ability of the sulfonamide nitrogen (compound
6) abolished binding. The addition of a piperidine ring
to the distal aryl ring (compound 7) increased affinity, but
only 2-fold, consistent with this substitution occurring in
a solvent-exposed region of the binding site.
Discussion
The most compelling result to emerge from this studyFigure 3. Lineweaver-Burk Plot of the Inhibition of AmpC by Com-
is the identification of a novel, competitive, noncovalentpound 1
inhibitor of AmpC -lactamase. All previously knownInhibitor concentrations were 0 M (), 15 M (), 60 M (H17009), 105
inhibitors form covalent adducts with the catalyticM (), and 150 M (). Each data point is the average of three
Ser64; with few exceptions [3, 17], all are eitherexperimental observations. The Ki value is 26 M.
-lactams [18–21] or molecules that mimic -lactams
[9, 22]. Conversely, compounds 1–3 form noncovalent
complexes using chemistry dissimilar to that found inpound 1 was 512g/ml. At this concentration compound
1 alone had no measurable antibiotic activity. classical inhibitors to bind to key substrate-recognition
residues in the AmpC active site.
Although compound 1 does not resemble a -lactamStructure-Activity Relationship of Compound 1
Several inhibitor moieties appeared to be key to enzyme by any standard classification scheme, it recapitulates
some familiar themes of -lactam recognition byrecognition based on the docking score and the crystal
structure. To investigate the energetic importance of -lactamases when viewed in the context of its complex
with AmpC. The sulfonamide group of compound 1the predicted and observed interactions, six analogs of
compound 1 were tested for inhibition (compounds 4–9; binds in the site that recognizes the ubiquitous C6(7)-
amide found in the R1 side chains of -lactams, whereTable 5). The carboxylate group of compound 1, which
hydrogen bonds with residues in the oxyanion or electro- it hydrogen bonds to two of the amide-recognizing resi-
dues, Asn152 and Ala318 (Figure 4B). Although thesephilic hole of AmpC, appears to be essential; binding
Table 2. Interactions in the Crystallographic and DOCK-Predicted Complexes of AmpC with 1
Distance (A˚)
AmpC/1 DOCK Prediction
Interaction Molecule 1 Molecule 2
S64N-O23 3.0 2.9 3.6
S64O-O23 2.9 2.8 3.0
A318O-O23 2.9 3.0 2.7
A318N-O23 2.8 2.9 2.6
A318N-O24 3.4 3.4 3.1
Wat403a-O24 2.9 2.7 2.5
Wat481-O24 — 2.7 —
S64O-O16 2.7 2.7 2.4
K67N-O16 3.1 3.1 4.3
N152N2-O17 2.7 2.7 2.6
A318O-N1 2.7 2.7 2.6
Centroid of Tyr221-centroid of phenyl ring of 1 5.5 5.8 4.6
a Wat403 is called Wat401 in molecule 1 of the asymmetric unit.
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Figure 4. Stereo View of the Active Site Region of the AmpC/1 Complex Determined to 1.94 A˚ Resolution
(A) The 2Fo  Fc electron density map is shown in blue, contoured at 1.0 . This figure was made with SETOR [41].
(B) Interactions observed between AmpC and compound 1 in the crystallographic complex. Cyan spheres represent water molecules. Dashed
yellow lines indicate hydrogen bonds. Atoms are colored as in Figure 2, except that the carbon atoms of compound 1 are colored orange.
(C) Overlay of the docked and crystallographic conformations of compound 1 in the AmpC site. Carbon atoms of compound 1 in the docked
conformation, green; carbon atoms of compound 1 in the crystal structure, orange.
hydrogen bonds resemble those made by the amide -lactamases with -lactams [18, 20, 21, 23–25]. Finally,
the terminal chlorophenyl ring of compound 1 stacksfunctionality of -lactams, the atom order of the sulfon-
amide group in compound 1 is the reverse of the amide with the conserved residue Tyr221. This interaction is
similar to those made by the aryl rings found in-lactamsfound in the R1 side chains of -lactams (Figures 1A
and 1B). Additionally, one of the oxygen atoms of the such as cephalothin [26], loracarbef [20], and ceftazi-
dime [25].carboxylate group of compound 1 binds in the oxyanion
[15] or electrophilic [3] hole of the -lactamase, hydro- It is interesting to consider how many of these interac-
tions were captured in the docking prediction that ledgen bonding to the main chain nitrogens of Ser64 and
Ala318 (Figure 4B). This interaction resembles those to the discovery of this inhibitor. The rmsd between the
docked and experimental structures varied from 1.7–made by the carbonyl oxygen atom of -lactams with
these residues in several acyl-enzyme complexes of 1.9 A˚, depending on which molecule in the asymmetric
Docking for Novel Inhibitors of -Lactamase
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Table 3. Crystallographic Summary for the Complex of AmpC/1
AmpC/1
Cell constants (A˚; 
) a  118.67 b  76.42 c  97.90;   116.63
Resolution (A˚) 1.94 (1.99–1.94)a
Unique reflections 56,580
Total observations 208,148
Rmerge (%) 5.5 (31.5)
Completeness (%)b 97.8 (95.1)
I	/I	 14.5 (4.2)
Resolution range for refinement (A˚) 20–1.94
Number of protein residues 713
Number of water molecules 352
Rmsd bond lengths (A˚) 0.009
Rmsd bond angles (
) 1.5
R factor (%) 17.3
Rfree (%)c 20.7
Average B factor, protein atoms (A˚2; molecule 1) 23.8
Average B factor, protein atoms (A˚2; molecule 2) 23.6
Average B factor, inhibitor atoms (A˚2; molecule 1) 29.8
Average B factor, inhibitor atoms (A˚2; molecule 2) 37.1
Average B factor, water molecules (A˚2) 31.1
a Highest resolution shell boundaries in parentheses. Subsequent values in parentheses are for that shell.
b Fraction of theoretically possible reflections observed.
c Rfree was calculated with 5% of reflections set aside randomly.
unit was used in the comparison. Notwithstanding this since, in the crystal structure, these groups hydrogen
bond extensively with the enzyme; any disruption ofquantitative difference, the two structures qualitatively
these interactions would be expected to adversely affectand visually resemble each other closely. Of the nine
affinity.hydrogen bonds observed in the crystal structure, seven
In our docking experiment, 13 previously determinedwere predicted in the docked complex, and both of the
structures of AmpC/ligand complexes were used to flagtwo major nonpolar interactions were predicted. The
hot spots for binding and to identify tightly bound watermajor difference between the docked and experimental
molecules [10]. Consensus binding sites were identifiedconfigurations is the rotation of the chlorophenyl ring
for an amide/aryl site, a carbonyl/hydroxyl site, a hy-by 60
 that results in a herringbone, or edge to face,
droxyl site, a carboxylate site, and a hydrophobic site.stacking interaction between this ring and Tyr221, rather
In their docked complexes, the three new inhibitors ex-than a face to face stacking interaction.
ploited these hot spots (Figure 2); for example, an oxy-The solvation-corrected docking energy score may
gen atom from the carboxylate group of compounds 1be apportioned among the atoms of the ligand using
and 3 and the sulfate group of compound 2 was pre-the atom by atom partitioning of the AMSOL solvation
dicted to bind in the carbonyl/hydroxyl site, and theand the docking energy calculations. These scores sug-
hydrophobic site was complemented with hydrophobicgest that the carboxylate and sulfonamide functionali-
portions of each of these compounds. Intriguingly, theties of compound 1 are key binding determinants.
new inhibitors took advantage of the consensus hotWhereas these atomic energies are not quantitative,
spots using functionality not found in the 13 ligandsthey can be useful as qualitative guides to subsequent
used to identify the hot spots in the first place. Forexperiments. Several analogs were tested to explore the
instance, compound 1 placed a sulfonamide in the am-importance of these groups to binding affinity (Table 5).
ide recognition site of AmpC, whereas none of the 13Substitution of the carboxylate with a neutral isostere
placed a sulfonamide there. Compound 1 used a carbox-abolished inhibition. Switching the order of the sulfon-
ylate group to bind in the oxyanion or electrophilic holeamide diminished inhibition 3-fold, suggesting that this
of the -lactamase, which had originally been definedunusual amide arrangement is nevertheless preferred in
as recognizing only carbonyl or hydroxyl groups. Com-this noncovalent inhibitor. These effects seem sensible,
pounds 2 and 3 placed a benzoaminothiazole ring in the
amide/aryl recognition site, but this functionality was
not represented by any of the 13 ligands.Table 4. Synergy of Compound 1 with the -Lactam Ampicillin
The inclusion of bound water molecules in our dockingAgainst AmpC Producing E. coli
experiment also came out of analysis of the 13 previous
Resistant Cells Sensitive Cells
complexes used to identify the consensus hot spots.MICa (g/ml) MIC (g/ml)
Water molecules included as part of the receptor influ-
Ampicillin 512 4 ence what ligands are identified in a docking calculation,
Ampicillin/1b 128 NDc both by acting as a point of interaction for the docked
Compound 1 	512 ND
molecules and by excluding them from occupying the
a Minimum inhibitory concentration. volume that the water itself occupies. Consequently,
b The ratio of ampicillin to inhibitor was 1:2. there is much interest in how water influences the results
c Not determined.
of docking and structure-based design calculations [27–
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29]. Based on the analysis of waters conserved in AmpCTable 5. Kinetic Characterization of Analogs of 1
structures, we treated three waters as nondisplaceable
Code Structure Ki (M) AmpC parts of the receptor: Wat403, Wat404, and Wat405.
Wat404 and Wat405 are relatively distant from the site
of docking and will not be considered further. Wat403
is at the center of the active site (Figure 2A). We used
this water in the docking calculation because it is highly
conserved in all AmpC structures (present in 29 of 30
molecules that we previously examined [10]) and be-
cause it is well coordinated by the enzyme. The inclusion
1 26
of this water appears to have influenced that calculation
beneficially, as it hydrogen bonds with the inhibitor in
both the docked and the crystallographic structures of
compound 1 bound to AmpC.
Compound 1 inhibits AmpC with a Ki value of 26 M.
Compared to more-traditional covalent inhibitors of
AmpC, this is a modest level of inhibition. Nevertheless,
the compound holds promise as a lead for drug discov-
4 60
ery; it explores novel chemical functionality, which it
uses to complement key recognition residues of the
-lactamase. The recognition “code” of the AmpC struc-
ture appears to be plastic [3]; not only are -lactams
recognized by highly conserved active site residues, but
compounds bearing very different functionality can also
bind. Notwithstanding its modest level of inhibition,
compound 1 reversed antibiotic resistance in bacterial
cell culture. The compound was selective for AmpC; it
5 		100a
did not significantly inhibit related serine proteases in
counterscreens. Finally, it is relatively “drug-like,” pass-
ing four of four Lipinski rules [30], and has several sites
for synthetic elaboration. The ability to discover such
inhibitors through structure-based techniques and the
correspondence between the docking prediction and
the experimental result hold promise for the develop-
ment of this and other families of novel inhibitors of
6 		100a
serine -lactamases. Such novel inhibitors are much
needed as -lactamase-mediated antibiotic resistance
continues to spread among bacterial pathogens.
Biological Implications
-lactamase enzymes are the most widespread resis-
tance mechanisms to -lactam antibiotics. Clinically
7 14
used inhibitors for these enzymes resemble substrates;
both contain a -lactam ring. For this reason, resistance
develops rapidly because mechanisms that depend on
recognition of the lactam ring already exist. A novel
inhibitor may evade such mechanisms, and, most impor-
tantly, it would not be hydrolyzed by -lactamases. In
an effort to discover novel inhibitors, we screened a
8 64
database of small molecules for complementarity to the
enzyme active site. Three novel inhibitors were identi-
fied; the best was a reversible, competitive inhibitor,
with a Ki of 26M. The structure of the complex between
AmpC and this inhibitor was determined by X-ray crys-
tallography and revealed that the inhibitor complements
the active site well through interactions with several key
active-site residues. These interactions resemble those
observed between the enzyme and -lactams and yet,
9 		100a
at the same time, are fundamentally different. It is only
in the context of the complex with the enzyme that anya No detectable inhibition at 100 M concentration of compound.
similarity can be discerned between compound 1 and
Docking for Novel Inhibitors of -Lactamase
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the addition of 0.875 nM enzyme and monitored in methacrylatea-lactam. This suggests that the “code” for recognition
cuvettes. No incubation effect was detected for any compound.by AmpC is plastic, and this plasticity can be used for
IC50 values were determined at 200 M substrate concentration. Kiinhibitor discovery. The identification of a novel, nonco-
values for the compounds were obtained by comparison of progress
valent inhibitor along with the structure of its complex curves in the presence and absence of inhibitor [36]. Sufficient inhib-
with AmpC provides an opportunity for structure-based itor was used to give at least 50% inhibition. For compound 1, a Ki
of 26M, consistent with the value of 23M determined by progressdesign efforts to improve binding affinity.
curve analysis, was determined by Lineweaver-Burk analysis of mul-
tiple substrate and inhibitor concentrations (Figure 3); a Ki value ofExperimental Procedures
28 M was determined from nonlinear fitting of the same data (data
not shown). We note that all compounds discussed here were wellDocking
behaved kinetically and do not fall into the category of aggregation-The Available Chemicals Directory was screened against molecule
based promiscuous inhibitors that we have recently described [37].2 of native AmpC (Protein Data Bank entry 1KE4) using the North-
The selectivity of compound 1 for AmpC was determined by mea-western University version [11, 12] of DOCK [13, 14]. To prepare the
suring its activity against -chymotrypsin (bovine pancreatic),site for docking, we removed all water and ion molecules, except
-trypsin (bovine pancreatic), and elastase (porcine pancreatic), allfor Wat403, Wat404, and Wat405. These specific water molecules
from Sigma (St. Louis). The substrates for -chymotrypsin (succinyl-were included as part of the receptor because they are observed
ala-ala-pro-phe-p-nitroanilide) and -trypsin (N-benzoyl-L-argininein nearly all AmpC structures and are expected to be tightly bound.
ethyl ester, BAEE) were also purchased from Sigma. The elastaseProtonation of receptor residues and water molecules was done
substrate (elastase substrate 1, MeOSuc-Ala-Ala-Pro-Val-p-nitroan-with Sybyl (Tripos, St. Louis). Positions of some protons were then
ilide) was purchased from Calbiochem (San Diego, CA). Substratesrotated manually to more appropriate orientations using MidasPlus
were diluted from 10 mM stock solutions in dimethylsulfoxide[31]. The sphere set used was based on ligand atom positions from
(DMSO), and all reactions were performed in 50 mM Tris buffer (pHan ensemble of structures of nine boronic acid inhibitors and four
7.0) 25
C. For -chymotrypsin, 200 M substrate was used; the-lactam molecules determined in complex with AmpC -lactamase
reactions were initiated by the addition of 10 l of a 0.1 mg/mlby X-ray crystallography [10]. This resulted in the cluster of 73
enzyme stock solution and monitored at 410 nm. For -trypsin, 200spheres, each of which represented a ligand atom position observed
M BAEE was used; the reactions were initiated by the addition ofin the X-ray structures used in the docking calculation. The spheres
5 l of a 0.2 mg/ml enzyme stock solution and monitored at 260were labeled based on the chemical functionality of the ligand atoms
nm. For elastase, 640 M substrate was used; the reactions werethey represented [32]. Force field and electrostatic grids were calcu-
initiated by the addition of 30l of a 0.2 mg/ml enzyme stock solutionlated with CHEMGRID [33] and DelPhi [34], respectively. DISTMAP
and monitored at 385 nm. Initial rate fits to the absorbance data forwas used to calculate the excluded volume grid [33].
the first 150 s of each reaction were used to determine reactionCalculated interaction energies in the docking calculation were
velocities.corrected for ligand desolvation [12] (Wei and B.K.S., unpublished
data) using AMSOL [35], which was also used to calculate ligand
partial atomic charges. Each orientation of the docked ligands was Crystal Growth and Structure Determination
Cocrystals of AmpC/1 were grown by vapor diffusion in hangingrefined with 100 iterations of rigid-body minimization [14]. The dis-
tance tolerance parameter for calculating orientations was set to drops equilibrated over 1.7 M potassium phosphate buffer (pH 8.7)
using microseeding techniques. The initial concentration of protein1.2 A˚. The ligand and receptor bin sizes were each 0.2 A˚, and ligand
and receptor overlap were also each 0.2 A˚. Chemical matching was in the drop was 95 M, and the concentration of the inhibitor was
1.2 mM. The inhibitor was added to the crystallization drop in a 4%used to specify how ligand atoms were to be matched to the spheres
[32]. To improve hydrogen bonding opportunities between active DMSO, 1.7 M potassium phosphate buffer (pH 8.7) solution. Crystals
appeared within 3–5 days after equilibration at 23
C.site residues and the ligands, the absolute magnitude of the partial
atomic charges of the following active site residues were increased Data were measured from a single crystal on the DND-CAT beam-
line (5IDB) of the Advanced Photon Source at Argonne National Labby 0.4 units and, in a second docking calculation, by 0.8 units:
Ser64O and HO; Gln120O1, HN1, and HN2; Tyr150OH and at 100 K using a Mar CCD detector. Prior to data collection, the
cocrystal of AmpC/1 was immersed in a cryoprotectant solution ofHOH; Asn152O1, HN1, and HN2; Tyr221OH and HOH; As-
n289O1, HN1, and HN2; Thr316O1 and HO; Ala318O and HN; 20% sucrose, 1.2 mM compound 1, and 1.7 M potassium phosphate
(pH 8.7) for about 20 s and then flash cooled in liquid nitrogen.Asn343O1, HN1, and HN2; Asn346O1, HN1, and HN2. For the
asparagine and glutamine residues, the charge increase was split Reflections were indexed, integrated, and scaled using the HKL
package [38] (Table 3). The space group was C2, with two AmpCamong the protons on the amide groups. The 500 top-scoring mole-
cules from each docking run were displayed with MidasPlus [31]. molecules in the asymmetric unit. The structure of the complex was
determined using a native apo AmpC structure (Protein Data BankFrom these two lists, we ordered and tested 56 compounds for their
ability to inhibit AmpC. entry 1KE4) [10], with water molecules and ions removed, as the
initial phasing model. The structure was refined using the maxi-
mum-likelihood target in CNS and included simulated-annealing,Enzymology
positional, and individual temperature factor refinement with a bulkAmpC from Escherichia coli was expressed and purified to homoge-
solvent correction [39]. A-weighted electron density maps wereneity as described [3]. Compound 1, 3-[(4-chloroanilino)sulfonyl]
calculated with CNS and used in steps of manual rebuilding withthiophene-2-carboxylic acid, compound 4, 2-methyl-4-[[(4-methyl-
the program O [40]. The inhibitor was built into the initial observedphenyl)sulfonyl]amino]thiophene-3-carboxylic acid, compound 5,
difference density in each active site of the asymmetric unit, andmethyl 3-[(4-chloroanilino)sulfonyl]thiophene-2-carboxylate, com-
the structure of the complex was further refined using CNS (Tablepound 6, 3-([4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazino]-
3). In the final model, molecule 1 contained 355 residues, molecule 2sulfonyl)thiophene-2-carboxylate, compound 7, 3-[(2-piperidino-
contained 358 residues, and there are 352 water molecules. Electronanilino)sulfonyl]thiophene-2-carboxylic acid, and compound 8, 2,5-
density for a third inhibitor molecule was observed between the twodimethyl-4-(2-thienylaminosulfonyl)furan-3-carboxylic acid, were
AmpC molecules, and the inhibitor was modeled into this electronobtained from Maybridge Chemical (Cornwall, UK). Compound 2,
density as well.3-(2-benzothiazolylthio)-1-propanesulfonic acid, and compound 9,
N-(4-methoxyphenyl)-2-nitro-benzenesulfonamide, were obtained
from Aldrich Chemical (Milwaukee, WI). Compound 3, 3-(2-benzothi- Microbiology Experiments
To test the inhibitory activity of compound 1, the compound wasazolylthio)propionic acid, was obtained from TCI America (Portland,
OR). All were used without further purification. Kinetic measure- dissolved in DMSO at a concentration of 50 mM and dilutions were
performed using Luria Broth growth medium. An adequate finalments with AmpC were performed in 50 mM Tris buffer (pH 7.0)
using nitrocefin as a substrate. The Km of nitrocefin for AmpC in this concentration at which to determine the MIC was obtained where
the concentration of DMSO was maintained below 5%. The MIC ofbuffer was determined to be 127 M. Reactions were initiated by
Structure
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the -lactam ampicillin, in the presence and absence of compound Costi, M.P., and Shoichet, B.K. (2001). Structure-based design
and in-parallel synthesis of inhibitors of AmpC beta-lactamase.1, was determined against JM109 E. coli expressing AmpC.
Chem. Biol. 8, 593–611.
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Accession Numbers
The structure of AmpC/1 has been deposited with the Protein Data
Bank as 1L2S.
